{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T16:14:14Z","timestamp":1775837654281,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:00:00Z","timestamp":1564531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi & Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.clinthera.2019.07.006","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T17:32:45Z","timestamp":1564680765000},"page":"1724-1736.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effect of Cefiderocol, a Siderophore Cephalosporin, on QT\/QTc Interval in Healthy Adult Subjects"],"prefix":"10.1016","volume":"41","author":[{"given":"Carlos","family":"Sanabria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Migoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay W.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie H.","family":"Stanworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Katsube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuaki","family":"Machida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitoshi","family":"Narukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutae","family":"Den Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.07.006_bib1","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","article-title":"Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes","volume":"67","author":"Schwartz","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2019.07.006_bib2","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"Yap","year":"2003","journal-title":"Heart"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2019.07.006_bib3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/cc6819","article-title":"An overview of harms associated with \u03b2-lactam antimicrobials: where do the carbapenems fit in?","volume":"12","author":"Owens","year":"2008","journal-title":"Crit Care"},{"key":"10.1016\/j.clinthera.2019.07.006_bib4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/jac\/45.5.557","article-title":"Quinolone-induced QT interval prolongation: a not-so-unexpected class effect","volume":"45","author":"Ball","year":"2000","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2019.07.006_bib5","first-page":"ii75","article-title":"Safety and tolerability of ertapenem","volume":"53","author":"Teppler","year":"2004","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2019.07.006_bib6","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1128\/AAC.02352-12","article-title":"Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval","volume":"57","author":"Riccobene","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2019.07.006_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcph.199","article-title":"Randomized, placebo-controlled study to assess the impact on QT\/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam","volume":"54","author":"Das","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.07.006_bib8","series-title":"Doribax (Doripenem for Injection) [prescribing Information]","year":"2015"},{"key":"10.1016\/j.clinthera.2019.07.006_bib9","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2019.07.006_bib10","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1128\/AAC.03098-15","article-title":"Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases","volume":"60","author":"Ito-Horiyama","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2019.07.006_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00093-17","article-title":"In\u00a0vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study)","volume":"61","author":"Hackel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2019.07.006_bib12","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/jac\/dkx049","article-title":"Activity of cefiderocol (S-649266) against carbapenem-resistant gram-negative bacteria collected from inpatients in Greek hospitals","volume":"72","author":"Falagas","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2019.07.006_bib13","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2019.07.006_bib14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/1469-0691.12655","article-title":"Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species","volume":"20","author":"Diene","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2019.07.006_bib15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3904\/kjim.2012.27.2.128","article-title":"Current epidemiology and growing resistance of Gram-negative pathogens","volume":"27","author":"Livermore","year":"2012","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.clinthera.2019.07.006_bib16","series-title":"Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.clinthera.2019.07.006_bib17","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2019.07.006_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02163-17","article-title":"Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects","volume":"62","author":"Saisho","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2019.07.006_bib19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/jcph.841","article-title":"Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment","volume":"57","author":"Katsube","year":"2017","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2019.07.006_bib20","series-title":"Guidance for Industry: E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs","author":"US Food and Drug Administration","year":"2005"},{"key":"10.1016\/j.clinthera.2019.07.006_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1476-5381.2009.00487.x","article-title":"The thorough QT\/QTc study 4 years after the implementation of the ICH E14 guidance","volume":"159","author":"Darpo","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2019.07.006_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01381-16","article-title":"Pharmacokinetic\/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function","volume":"61","author":"Katsube","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819303492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819303492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:42Z","timestamp":1758963102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819303492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0149291819303492"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.07.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Cefiderocol, a Siderophore Cephalosporin, on QT\/QTc Interval in Healthy Adult Subjects","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}